Key result
Oral antiarrhythmic drugs, specifically Vaughan-Williams Class Ic and III agents, require careful pharmacist management for appropriate dosing, administration, and monitoring in the outpatient setting.
This review highlights the vital role of pharmacists in managing the initiation, maintenance, and monitoring of Class Ic and III antiarrhythmic drugs in outpatient settings.
May enhance outpatient safety; leaves open prospective trials on pharmacist protocols.
A role for oral antiarrhythmic drugs (AADs) remains in clinical practice for patients with atrial and ventricular arrhythmias in spite of advances in nonpharmacologic therapy. Pharmacists play a vital role in the appropriate use of AAD dosing, administration, adverse effects, interactions, and monitoring. Pharmacists who are involved in providing care to patients with cardiac arrhythmias must remain updated regarding the efficacy and safety of the most commonly used AADs. This review will address key issues for appropriate initiation and maintenance of commonly selected Vaughan-Williams Class Ic and III agents in the outpatient setting.
No takes yet. Share an insight, caveat, or question.
Parker et al. (2015) conducted a review in Atrial and ventricular arrhythmias. Oral antiarrhythmic drugs (Vaughan-Williams Class Ic and III agents) was evaluated. Oral antiarrhythmic drugs, specifically Vaughan-Williams Class Ic and III agents, require careful pharmacist management for appropriate dosing, administration, and monitoring in the outpatient setting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: